Stockholm Medical Cannabis Conference

The Upcoming Unavoidable Divergence of the Medical and Recreational Cannabis Markets

Medical and recreational cannabis markets are likely to diverge further as scientific research reveals more therapeutic benefits of cannabis and its derivatives. This divergence stems from the demand for specific, evidence-based treatments for various medical conditions, which require accurate dosing, controlled formulations, and strict quality standards. On the other hand, recreational cannabis products are mainly designed for consumer satisfaction and preferences, with a wider range of product types and a continuous focus on THC potencies.

Updated clinical guidelines for managing chronic pain and co-occurring conditions with Cannabinoid-Based Medicines

Researchers conducted a systematic review of studies investigating the use of cannabinoid-based medicines (CBMs) for chronic pain management and developed clinical practice guidelines based on the evidence. The review found that CBMs may provide benefits for chronic pain reduction, especially for neuropathic pain, and help with some co-occurring conditions. However, CBMs may cause some adverse events, and the optimal use of CBMs for chronic pain and co-occurring conditions is not clear. The guidelines provide practical recommendations for clinicians on patient education, assessment, dosing, administration routes, monitoring, and discontinuation of CBMs.